AAMU
EW icon

Amundi Asset Management US’s Edwards Lifesciences EW Stock Holding History

Amundi Asset Management US’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$385M Sell
4,599,422
-1,420,867
-24% -$120M 0.29% 75
2020
Q4 		$549M Buy
6,020,289
+375,597
+7% +$31.2M 0.47% 40
2020
Q3 		$451M Buy
5,644,692
+556,293
+11% +$43.4M 0.47% 41
2020
Q2 		$352M Buy
5,088,399
+753,426
+17% +$53.5M 0.42% 52
2020
Q1 		$273M Buy
4,334,973
+439,710
+11% +$31.7M 0.47% 48
2019
Q4 		$303M Buy
3,895,263
+727,809
+23% +$56.8M 0.36% 65
2019
Q3 		$232M Sell
3,167,454
-776,601
-20% -$54.6M 0.35% 66
2019
Q2 		$243M Buy
3,944,055
+347,643
+10% +$21M 0.2% 118
2019
Q1 		$229M Sell
3,596,412
-213,669
-6% -$12.2M 0.32% 71
2018
Q4 		$195K Sell
3,810,081
-121,908
-3% -$6.17M 0.18% 90
2018
Q3 		$228M Buy
3,931,989
+177,219
+5% +$8.67M 0.3% 80
2018
Q2 		$182M Buy
3,754,770
+564,198
+18% +$26.3M 0.26% 94
2018
Q1 		$148M Sell
3,190,572
-156,402
-5% -$6.79M 0.24% 100
2017
Q4 		$126M Buy
3,346,974
+1,275,558
+62% +$46.8M 0.19% 130
2017
Q3 		$75.5M Buy
2,071,416
+16,989
+0.8% +$648K 0.24% 96
2017
Q2 		$81M Buy
2,054,427
+112,956
+6% +$4.12M 0.27% 89
2017
Q1 		$60.9M Sell
1,941,471
-2,595,606
-57% -$81.3M 0.21% 102
2016
Q4 		$142M Sell
4,537,077
-750,525
-14% -$24.3M 0.5% 54
2016
Q3 		$212M Buy
5,287,602
+176,010
+3% +$6.63M 0.76% 39
2016
Q2 		$170M Sell
5,111,592
-37,293
-0.7% -$1.28M 0.62% 47
2016
Q1 		$151M Buy
5,148,885
+414,219
+9% +$11.4M 0.56% 51
2015
Q4 		$125M Buy
4,734,666
+3,519,150
+290% +$91.4M 0.47% 63
2015
Q3 		$28.8M Buy
1,215,516
+4,608
+0.4% +$111K 0.12% 172
2015
Q2 		$28.7M Buy
1,210,908
+236,070
+24% +$5.33M 0.11% 198
2015
Q1 		$23.1M Sell
974,838
-79,302
-8% -$1.78M 0.08% 241
2014
Q4 		$22.4M Sell
1,054,140
-118,140
-10% -$2.37M 0.08% 243
2014
Q3 		$20M Sell
1,172,280
-46,974
-4% -$742K 0.08% 253
2014
Q2 		$17.4M Sell
1,219,254
-317,154
-21% -$4.3M 0.07% 274
2014
Q1 		$19M Buy
1,536,408
+459,588
+43% +$5.3M 0.07% 262
2013
Q4 		$11.8M Buy
+1,076,820
New +$12.1M 0.05% 310

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Amundi Asset Management US's EW Position: Q1 2021 in Review

Amundi Asset Management US reduced its Edwards Lifesciences (EW) stake by 24% in Q1 2021, selling an estimated $120M and leaving 4,599,422 shares worth $385M. The position accounts for 0.29% of the portfolio, ranked #75.

Amundi Asset Management US first reported a position in EW in Q4 2013 and has held it in 30 quarters since. The position peaked at $549M in Q4 2020. 1,143 funds tracked by Wall St. Rank hold EW as of Q1 2021.

  • Amundi Asset Management US held 4,599,422 shares of Edwards Lifesciences worth $385M as of Q1 2021.
  • Amundi Asset Management US sold 1,420,867 Edwards Lifesciences shares in Q1 2021, an estimated $120M.
  • Edwards Lifesciences made up 0.29% of Amundi Asset Management US's portfolio in Q1 2021, its #75 holding.
  • Amundi Asset Management US first reported a position in Edwards Lifesciences in Q4 2013 and has held it in 30 quarters since.
  • Amundi Asset Management US's Edwards Lifesciences position peaked at $549M in Q4 2020.
  • 1,143 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.